Description
A macrolide antibiotic; active against S. pneumoniae, S. aureus, N. gonorrhoeae, M. pneumoniae, H. pylori, C. trachomatis, and H. influenzae in vitro (MIC90s = S. pyogenes, S. pneumoniae, E. faecalis, or H. influenzae infection (ED50s = 0.78, 8.7, 12.7, and 30.3 mg/kg, respectively); decreases plasma levels of IL-6, TNF-α, and IL-1β and increases survival in mouse model of LPS-induced sepsis at 100 mg/kg
Formal name: (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-13-[(2,6-dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one
Synonyms: CP 62,993
Molecular weight: 749
CAS: 83905-01-5
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals||Research Area|Immunology & Inflammation|Innate Immunity|Sepsis/Shock||Research Area|Infectious Disease|Bacterial Diseases||Research Area|Infectious Disease|Parasitic Diseases|Malaria